Lumpy Skin Disease Virus Knockout Mutant Vaccine
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current vaccines for lumpy skin disease (LSD) in cattle, sheep, and goats have limitations such as vaccine failure, shorter immunity periods, and variable antibody production, necessitating annual vaccinations and posing economic challenges due to disease-induced morbidity and mortality.
Innovation Solution
A live-attenuated recombinant lumpy skin disease virus (LSDV) knock-out mutant is developed by inactivating the interleukin-10-like gene, which is used to create a pharmaceutical composition that elicits a protective immune response against LSD, sheep pox, and goat pox, offering potential cross-protection across capripoxvirinae genus diseases.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current vaccines are used for lumpy skin disease control, then vaccination coverage is maintained, but vaccine failure occurs and immunity period is short requiring annual vaccinations
Solution Approach 1:
The patent removes the interleukin-10-like gene (ORF005) from the LSDV genome to create a knockout mutant vaccine. This extraction of the immunomodulatory gene eliminates the virus's ability to suppress host immune responses, thereby extending the duration of protective immunity while maintaining vaccine reliability
Solution Approach 2:
The patent modifies the viral genome by deleting a specific gene sequence (ORF005), changing the immunological parameters of the virus. This genetic parameter change results in enhanced immunogenicity and prolonged immunity duration without requiring annual re-vaccination
2Object-affected harmful factors
If attenuated vaccine strains are used, then safety is improved, but antibody production becomes variable and immune response is reduced
Solution Approach 1:
By removing the interleukin-10-like gene that suppresses immune responses, the vaccine maintains safety through attenuation while simultaneously enhancing antibody production by eliminating the immunosuppressive mechanism, thus resolving the contradiction between safety and immunogenicity
Solution Approach 2:
The patent converts the harmful immunosuppressive effect of the interleukin-10-like gene into a benefit by deleting it. The gene's original function of suppressing immune responses is transformed into enhanced immune stimulation, increasing antibody production while maintaining vaccine safety
3Reliability
If gene knockout is performed to attenuate the virus, then vaccine efficacy is improved, but there is risk of generating more virulent virus
Solution Approach 1:
The targeted deletion of the interleukin-10-like gene specifically removes immunosuppressive function while preserving other viral functions, achieving enhanced vaccine efficacy without inadvertently increasing virulence through uncontrolled genetic modification
Solution Approach 2:
The patent applies localized genetic modification by deleting only the specific interleukin-10-like gene (ORF005) while leaving the rest of the viral genome intact. This localized change selectively enhances immunogenicity without affecting other viral properties that could increase virulence
Data Source
Figure 1
Figure 2
Figure 3A~3C
AI summary
This invention relates to a live-attenuated recombinant lumpy skin disease virus knock-out mutant, wherein the interieukin-10-like gene or a functional part of the gene has been inactivated in the viral genome. The invention specifically relates to the recombinant lumpy skin disease virus knock-out mutant, pharmaceutical compositions comprising the knock-out mutant, methods of producing the knock out mutant and uses of the knock-out mutant.